Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy - PubMed
6 hours ago
- #immunometabolism
- #diabetic cardiomyopathy
- #AZD1656
- AZD1656, a glucokinase activator, improves cardiac function in type 2 diabetic cardiomyopathy (dbCM).
- Treatment with AZD1656 for 6 weeks in db/db mice enhanced myocardial performance and reduced infarct size.
- AZD1656 restores mitochondrial metabolism and reduces fibrosis in the diabetic heart.
- The drug promotes infiltration of regulatory T cells, remodeling the cardiac immune landscape.
- Targeting immunometabolic pathways with AZD1656 offers a therapeutic strategy for diabetic heart dysfunction.